Apollomics Inc Cl A (APLM)

$14.65 0.00 (N/A)
Market Cap 32.17M
Revenue (ttm) 8.50M
Net Income (ttm) -10.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -128.71%
Debt to Equity Ratio 0.00
Volume 15,900
Avg Vol 6,996
Day's Range N/A - N/A
Shares Out 2.20M
Stochastic %K 41%
Beta 1.53
Analysts Strong Buy
Price Target $6.50

Company Profile

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; APL-102, an oral active, small molecule multip...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 209 4055
Fax: 650 288 1674
Address:
989 East Hillsdale Blvd., Suite 220, Foster City, United States
Joby099
Joby099 Apr. 27 at 9:24 PM
$POET $CTNT $APLM $ADTX
0 · Reply
Joby099
Joby099 Apr. 27 at 9:48 AM
$POET $CTNT $APLM $ADTX
0 · Reply
Joby099
Joby099 Apr. 27 at 1:00 AM
$POET $CTNT $APLM $ADTX
0 · Reply
Joby099
Joby099 Apr. 26 at 9:11 PM
$POET $CTNT $APLM $ADTX He explains market conditions and why setups make sense. Recommended! https://www.youtube.com/watch?v=a1FfK8sbACY
0 · Reply
AtlasAnalysis
AtlasAnalysis Apr. 16 at 2:24 PM
$APLM glued to support. Volume or catalyst turns it around to 20+
0 · Reply
DARKP00L
DARKP00L Apr. 1 at 11:13 AM
$APLM 07:11 on Apr. 01 2026 Apollomics Enters Into $2M Unsecured Convertible Promissory Note With Its Chairman And CEO Hung-Wen Chen On March 30 #tradeideas
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 20 at 7:55 PM
$APLM RSI: 29.09, MACD: -0.1817 Vol: 0.62, MA20: 19.97, MA50: 19.84 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 27 at 5:50 PM
$APLM RSI: 60.32, MACD: 0.3709 Vol: 0.98, MA20: 19.74, MA50: 19.37 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
EmergingMarketDebt
EmergingMarketDebt Feb. 17 at 12:25 PM
$APLM Obscure micro-cap; likely a shell with negligible operations.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 25 at 3:38 AM
$APLM RSI: 43.64, MACD: 0.3708 Vol: 1.25, MA20: 20.07, MA50: 18.06 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Latest News on APLM
Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress

Apr 27, 2026, 8:00 AM EDT - 16 days ago

Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress

Apollomics Inc. Announces $2.0 Million Bridge Financing

Apr 1, 2026, 7:00 AM EDT - 6 weeks ago

Apollomics Inc. Announces $2.0 Million Bridge Financing

Apollomics files to sell 279,775 Class A Ordinary shares for holders

2026-03-09T21:20:09.000Z - 2 months ago

Apollomics files to sell 279,775 Class A Ordinary shares for holders

Apollomics Inc trading resumes

2025-12-30T21:00:11.000Z - 4 months ago

Apollomics Inc trading resumes

Apollomics Inc trading halted, volatility trading pause

2025-12-30T20:55:19.000Z - 4 months ago

Apollomics Inc trading halted, volatility trading pause

Apollomics Reports First Half 2025 Financial Results

Dec 22, 2025, 4:05 PM EST - 5 months ago

Apollomics Reports First Half 2025 Financial Results

Apollomics Inc trading resumes

2025-11-21T16:50:25.000Z - 6 months ago

Apollomics Inc trading resumes

Apollomics Inc trading halted, volatility trading pause

2025-11-21T16:45:23.000Z - 6 months ago

Apollomics Inc trading halted, volatility trading pause

Apollomics announces settlement of Cayman litigation

2025-11-19T22:45:12.000Z - 6 months ago

Apollomics announces settlement of Cayman litigation

Apollomics Announces Settlement of Cayman Litigation

Nov 19, 2025, 5:38 PM EST - 6 months ago

Apollomics Announces Settlement of Cayman Litigation

Apollomics Inc trading resumes

2025-11-18T16:15:24.000Z - 6 months ago

Apollomics Inc trading resumes

Apollomics Inc trading halted, volatility trading pause

2025-11-18T16:10:11.000Z - 6 months ago

Apollomics Inc trading halted, volatility trading pause

Apollomics Announces Changes to its Board of Directors and Composition of Committees

Nov 17, 2025, 11:00 PM EST - 6 months ago

Apollomics Announces Changes to its Board of Directors and Composition of Committees

Apollomics Inc trading resumes

2025-10-31T14:11:03.000Z - 6 months ago

Apollomics Inc trading resumes

Apollomics Inc trading halted, volatility trading pause

2025-10-31T14:06:22.000Z - 6 months ago

Apollomics Inc trading halted, volatility trading pause

Apollomics Inc trading resumes

2025-10-16T17:15:20.000Z - 7 months ago

Apollomics Inc trading resumes

Apollomics Inc trading halted, volatility trading pause

2025-10-16T17:10:24.000Z - 7 months ago

Apollomics Inc trading halted, volatility trading pause

Apollomics says securities to remain listed on Nasdaq

2025-10-15T18:45:14.000Z - 7 months ago

Apollomics says securities to remain listed on Nasdaq

Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation

Oct 15, 2025, 2:36 PM EDT - 7 months ago

Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation

nasdaq resumes trading in Apollomics

2025-10-14T20:10:22.000Z - 7 months ago

nasdaq resumes trading in Apollomics

Apollomics reverses wind-up plans, provides operational update

2025-10-14T10:00:33.000Z - 7 months ago

Apollomics reverses wind-up plans, provides operational update

Apollomics, Inc. Company Operational Continuity Update

Oct 13, 2025, 9:22 PM EDT - 7 months ago

Apollomics, Inc. Company Operational Continuity Update

Nasdaq halts Apollomics

2025-09-17T21:56:00.000Z - 8 months ago

Nasdaq halts Apollomics

NDAQ

Apollomics Inc trading resumes

2025-05-23T18:25:25.000Z - 1 year ago

Apollomics Inc trading resumes

Apollomics Inc trading halted, volatility trading pause

2025-05-23T18:20:12.000Z - 1 year ago

Apollomics Inc trading halted, volatility trading pause

Apollomics Inc trading resumes

2025-04-15T14:04:48.000Z - 1 year ago

Apollomics Inc trading resumes

Apollomics Inc trading halted, volatility trading pause

2025-04-15T13:51:02.000Z - 1 year ago

Apollomics Inc trading halted, volatility trading pause

Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

Apr 3, 2025, 4:05 PM EDT - 1 year ago

Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Dec 20, 2024, 8:00 AM EST - 1 year ago

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Dec 10, 2024, 4:05 PM EST - 1 year ago

Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

Aug 14, 2024, 6:00 AM EDT - 1 year ago

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

Jul 16, 2024, 4:47 PM EDT - 1 year ago

Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

Apollomics Announces Updated Strategic Focus and Leadership Team Changes

Jul 3, 2024, 8:00 AM EDT - 2 years ago

Apollomics Announces Updated Strategic Focus and Leadership Team Changes

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

Apr 25, 2024, 8:30 AM EDT - 2 years ago

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Apr 10, 2024, 7:00 AM EDT - 2 years ago

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Mar 28, 2024, 7:00 AM EDT - 2 years ago

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer

Mar 4, 2024, 7:00 AM EST - 2 years ago

Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer

Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 7, 2024, 7:00 AM EST - 2 years ago

Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Jan 19, 2024, 4:15 PM EST - 2 years ago

Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Apollomics to Participate in a Fireside Chat at the B. Riley Securities' 2024 Virtual Oncology Conference

Jan 17, 2024, 4:30 PM EST - 2 years ago

Apollomics to Participate in a Fireside Chat at the B. Riley Securities' 2024 Virtual Oncology Conference

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Jan 3, 2024, 7:00 AM EST - 2 years ago

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Apollomics to Present at the 2024 Biotech Showcase

Jan 2, 2024, 4:30 PM EST - 2 years ago

Apollomics to Present at the 2024 Biotech Showcase

Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

Nov 29, 2023, 7:30 AM EST - 2 years ago

Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)

Nov 28, 2023, 7:00 AM EST - 2 years ago

Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)

Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer

Nov 16, 2023, 8:30 AM EST - 2 years ago

Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer

Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation

Oct 31, 2023, 8:30 AM EDT - 2 years ago

Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation

Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion

Oct 26, 2023, 8:50 AM EDT - 2 years ago

Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion

Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%

Oct 23, 2023, 8:30 AM EDT - 2 years ago

Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%

Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023

Oct 16, 2023, 6:55 PM EDT - 2 years ago

Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023

Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update

Sep 28, 2023, 4:17 PM EDT - 2 years ago

Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update

Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 7:00 AM EDT - 2 years ago

Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R.

Apr 11, 2023, 8:30 AM EDT - 3 years ago

Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R.

Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination

Jan 13, 2023, 4:13 PM EST - 3 years ago

Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination

Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business Combination

Oct 7, 2022, 4:05 PM EDT - 3 years ago

Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business Combination

Joby099
Joby099 Apr. 27 at 9:24 PM
$POET $CTNT $APLM $ADTX
0 · Reply
Joby099
Joby099 Apr. 27 at 9:48 AM
$POET $CTNT $APLM $ADTX
0 · Reply
Joby099
Joby099 Apr. 27 at 1:00 AM
$POET $CTNT $APLM $ADTX
0 · Reply
Joby099
Joby099 Apr. 26 at 9:11 PM
$POET $CTNT $APLM $ADTX He explains market conditions and why setups make sense. Recommended! https://www.youtube.com/watch?v=a1FfK8sbACY
0 · Reply
AtlasAnalysis
AtlasAnalysis Apr. 16 at 2:24 PM
$APLM glued to support. Volume or catalyst turns it around to 20+
0 · Reply
DARKP00L
DARKP00L Apr. 1 at 11:13 AM
$APLM 07:11 on Apr. 01 2026 Apollomics Enters Into $2M Unsecured Convertible Promissory Note With Its Chairman And CEO Hung-Wen Chen On March 30 #tradeideas
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 20 at 7:55 PM
$APLM RSI: 29.09, MACD: -0.1817 Vol: 0.62, MA20: 19.97, MA50: 19.84 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 27 at 5:50 PM
$APLM RSI: 60.32, MACD: 0.3709 Vol: 0.98, MA20: 19.74, MA50: 19.37 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
EmergingMarketDebt
EmergingMarketDebt Feb. 17 at 12:25 PM
$APLM Obscure micro-cap; likely a shell with negligible operations.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 25 at 3:38 AM
$APLM RSI: 43.64, MACD: 0.3708 Vol: 1.25, MA20: 20.07, MA50: 18.06 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BSMARKET
BSMARKET Jan. 14 at 3:03 PM
$APLM $THH $ANPA
0 · Reply
BSMARKET
BSMARKET Jan. 13 at 11:52 PM
$APLM will follow $THH $ANPA same territory
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 31 at 4:13 PM
$APLM
0 · Reply
caprihunter
caprihunter Dec. 29 at 3:44 PM
$MMA $HIT.X $CABR $APLM $PRAX
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 26 at 7:27 PM
$APLM RSI: 59.40, MACD: 0.2437 Vol: 1.53, MA20: 16.28, MA50: 18.20 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
RiskPoolingR
RiskPoolingR Dec. 25 at 7:59 AM
$APLM Market tolerance narrows as uncertainty lingers, while management calibrates resource allocation to real demand signals. Clear follow‑through could unlock sustainable re‑rating.
0 · Reply
TonySuprano
TonySuprano Dec. 16 at 8:36 PM
$APLM
0 · Reply
DARKP00L
DARKP00L Dec. 12 at 5:00 PM
$APLM 11:43 on Dec. 12 2025 On December 11, 2025 Apollomics Issued Formal Notice Of Termination To Edison Oncology Related To Development And Commercialization Of APL-122; Terminating Agreement On Basis That Edison Failed To Fulfill Certain Material Performance & Reporting Obligations; Co Does Not Expect Termination To Have Material Adverse Effect On Its Overall Financial Condition Or Results Of Operations #tradeideas
0 · Reply